Literature DB >> 30210608

Neuroprotective effect of recombinant adeno-associated virus human thioredoxin-PR39 on acute cerebral infarction in rats.

Yu-Dong Guo1, Teng Huang2, Wen-Hua Sheng3, Yun-Fei Guan4, Yi-Feng Du5, You-Ting Lin5, Xi-Yun Ruan5.   

Abstract

The recombinant adeno-associated virus human thioredoxin-PR39 (rAAV/hTRX-PR39) has been demonstrated to have a protective effect on hypoxic cells. The present study aimed to explore the potential effect of rAAV/hTRX-PR39 on acute cerebral infarction in rats. Middle cerebral artery occlusion (MCAO) model rats were produced and divided into three groups: Normal saline group, empty virus group (rAAV, without hTRX-PR39 cDNA) and rAAV/hTRX-PR39 group. Hematoxylin and eosin staining and electron microscopy observation were used to assess the morphological changes of ischemic brain tissue during different periods. Immunohistochemistry was employed to detect the expression of CD34 to reflect angiogenesis of ischemic brain tissue. Rats treated with rAAV/hTRX-PR39 showed an alleviated degree of ischemic brain edema relative to that in control groups, suggesting PR39 can ameliorate brain damage after cerebral ischemia. In the rAAV/hTRX-PR39 group, CD34-positive cells were significantly increased in ischemic brain tissues compared to control groups. Furthermore, CD34-positive cells were primarily observed around the perivascular in ischemic brain, indicating the angiogenesis role of PR39 in ischemic brain. The present findings suggest that PR39 could effectively ameliorate ischemic brain damage and promote angiogenesis, which may contribute to the treatment of acute cerebral infarction.

Entities:  

Keywords:  PR39; acute cerebral infarction; adeno-associated virus; gene fusion; gene therapy; thioredoxin

Year:  2018        PMID: 30210608      PMCID: PMC6122552          DOI: 10.3892/etm.2018.6456

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

Review 1.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

2.  Potential role of recombinant adeno-associated virus human thioredoxin-PR39 in cell and vascular protection against hypoxia.

Authors:  Xi-Yun Ruan; Ying-Chun Liang; Bin DU; You-Ting Lin; Yu-Dong Guo; Jing Zhao; Shan Li; Ji-Feng Li; Qin-Jian Sun; Yi-Feng DU
Journal:  Exp Ther Med       Date:  2015-02-17       Impact factor: 2.447

3.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

4.  Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling.

Authors:  Ebo D De Muinck; Norbert Nagy; Daniela Tirziu; Masahiro Murakami; Narasimman Gurusamy; Shyamal K Goswami; Satish Ghatpande; Richard M Engelman; Michael Simons; Dipak K Das
Journal:  Antioxid Redox Signal       Date:  2007-04       Impact factor: 8.401

5.  Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.

Authors:  Corina Borghouts; Christian Kunz; Natalia Delis; Bernd Groner
Journal:  Mol Cancer Res       Date:  2008-02       Impact factor: 5.852

6.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

Review 7.  Thioredoxin: a key regulator of cardiovascular homeostasis.

Authors:  Hideyuki Yamawaki; Judith Haendeler; Bradford C Berk
Journal:  Circ Res       Date:  2003-11-28       Impact factor: 17.367

Review 8.  Adeno-associated virus (AAV) gene therapy for neurological disease.

Authors:  Marc S Weinberg; R Jude Samulski; Thomas J McCown
Journal:  Neuropharmacology       Date:  2012-03-17       Impact factor: 5.250

9.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

10.  Recombinant adeno-associated virus delivered human thioredoxin-PR39 prevents hypoxia-induced apoptosis of ECV304 cells.

Authors:  Xiyun Ruan; Zhenguo Yuan; Yifeng Du; Guangxiao Yang; Quanying Wang
Journal:  Neural Regen Res       Date:  2012-03-25       Impact factor: 5.135

View more
  1 in total

Review 1.  Physical-Exercise-Induced Antioxidant Effects on the Brain and Skeletal Muscle.

Authors:  Jennyffer Souza; Rodrigo Augusto da Silva; Débora da Luz Scheffer; Rafael Penteado; Alexandre Solano; Leonardo Barros; Henning Budde; Andrés Trostchansky; Alexandra Latini
Journal:  Antioxidants (Basel)       Date:  2022-04-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.